SCHEMBL4900969

SCHEMBL4900969

COc1ccc(-c2c(C(N)=O)[nH]c3cc(OC)c(OC)cc23)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 11/20 0.70
KDM4E B2RXH2 4/20 0.53
MAPT P10636 4/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 3/20 0.53
GAA P10253 3/20 0.47
NPSR1 Q6W5P4 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
USP2 O75604 2/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
JAK2 O60674 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
HSP90AA1 P07900 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14527816 0.89 MAP2 (0.63) MAP2KDM4EMAPTALDH1A1HPGD
SCHEMBL4592067 0.88 MAP2 (0.61) MAP2KDM4EMAPTALDH1A1HPGD
SCHEMBL4591604 0.88 KDM4E (0.54) MAP2KDM4EMAPTALDH1A1HPGD
SCHEMBL5157162 0.87 MAPT (0.54) MAP2KDM4EMAPTALDH1A1HPGD
SCHEMBL5159252 0.86 KDM4E (0.63) MAP2KDM4EMAPTALDH1A1HPGD
SCHEMBL5427113 0.82 MAPT (0.53) MAP2KDM4EMAPTALDH1A1HPGD
SCHEMBL4601191 0.81 MCL1 (0.50) MAP2KDM4EMAPTALDH1A1HPGD
SCHEMBL5425215 0.79 MEN1 (0.55) MAP2KDM4EMAPTALDH1A1HPGD
SCHEMBL5157945 0.79 MEN1 (0.55) MAP2KDM4EMAPTALDH1A1HPGD
SCHEMBL4592128 0.78 GPR35 (0.50) KDM4EMAPTALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080226718-A1 Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases BRANE DISCOVERY S.R.L (IT) 2008-09-18 US claimed
US-20080317857-A1 V-Atpase Inhibitors of Use in the Treatment of Septic Shock BRANE DISCOVERY S.R.L. (IT) 2008-12-25 US disclosed
US-20080317857-A1 V-Atpase Inhibitors of Use in the Treatment of Septic Shock BRANE DISCOVERY S.R.L. (IT) 2008-12-25 US disclosed
US-20080226718-A1 Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases BRANE DISCOVERY S.R.L (IT) 2008-09-18 US disclosed
US-20080226718-A1 Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases BRANE DISCOVERY S.R.L (IT) 2008-09-18 US disclosed
US-20080226718-A1 Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases BRANE DISCOVERY S.R.L (IT) 2008-09-18 US disclosed
US-20070248672-A1 Indole and Azaindole Derivatives with Antitumor Action NIKEM RESEARCH S.R.L. (IT) 2007-10-25 US disclosed
EP-1750687-A2 INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION NIKEM RESEARCH S.R.L. (IT) 2007-02-14 EP disclosed
WO-2005105213-A2 INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION NIKEM RESEARCH S.R.L. (IT) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070248672-A1 Indole and Azaindole Derivatives with Antitumor Action IDO1, IDO2, INMT MAP2 2318/4885KDM4E 512/4885MAPT 4170/4885
US-20080226718-A1 Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases IDO1, IDO2, INMT MAP2 1666/4885KDM4E 902/4885MAPT 4048/4885
US-20080317857-A1 V-Atpase Inhibitors of Use in the Treatment of Septic Shock ATP6V1E1, ATP6V1H, ATP6V1G1 MAP2 2101/4885KDM4E 3457/4885MAPT 4121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.